Mymee

Executive Summary

Mymee is a digital health company leveraging AI to analyze the exposome—environmental and lifestyle factors—to identify individualized triggers for patients with autoimmune conditions such as rheumatoid arthritis, lupus, psoriatic arthritis, ankylosing spondylitis, and long COVID. Founded in 2016 and headquartered in New York, Mymee aims to help patients with uncontrolled symptoms despite standard treatment. The platform provides personalized insights that patients and physicians can use to adjust behaviors and reduce symptom burden. While the company has not disclosed funding rounds or revenue, its focus on a growing underserved market—chronic autoimmune diseases—positions it for potential growth. The lack of publicly available clinical data or partnerships makes near-term visibility limited, but the underlying technology and addressable market support a moderate conviction in the company's long-term viability.

Upcoming Catalysts (preview)

• Q4 2026Publication of real-world evidence study demonstrating symptom improvement40% success
• 2027Strategic partnership with a large pharmaceutical company for bundled digital therapeutic offering30% success
• Q2 2027Series A or B fundraise to scale commercial operations50% success